AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
(From US Newswire)
To: Metro Desk, Health Reporter
Contact: Tyler Prell of The Hauser Group for IREF, 202-518-8047 (8 a.m. to 6 p.m. EST) or 202-210-1203 (all other times)
SAN BRUNO, Calif., Jan. 25 /U.S. Newswire/ -- Aprotinin -a a drug approved by the FDA, marketed internationally for the last 13 years, and given to an estimated one million surgery patients to limit bleeding -a has now been proven to double a patient's risk of kidney failure, and increase the risk of heart attack, heart failure, and stroke. These results -a published in this week's New England Journal of Medicine -a are based on an independent (non-commercial), observational study conducted by The Ischemia Research and Education Foundation (IREF), in association with the McSPI Research Group -- nonprofit biomedical research organizations dedicated to saving and extending lives.
"Our study provides compelling evidence of aprotinin's serious risks, and strongly suggests discontinuation of use and replacement with either of the two alternative generic and far less costly medications proven safe in this study," said IREF and McSPI founder and principal scientist, Dennis T. Mangano, Ph.D., M.D. "Certainly, our findings -a coming on the heels of the Vioxx experience -a indicate that the problem of drug safety is not only ubiquitous,…